Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20734753 | 0.87 | IDO1 (0.39) | MEN1KMT2ALMNAIDO1ALDH1A1 | |
| SCHEMBL8011467 | 0.85 | MEN1 (0.54) | MEN1KMT2ALMNAEPHX1MAPK1 | |
| SCHEMBL9344493 | 0.85 | MEN1 (0.61) | MEN1KMT2ALMNAIDO1EPHX1 | |
| SCHEMBL13799444 | 0.82 | MEN1 (0.50) | MEN1KMT2ALMNAIDO1EPHX1 | |
| SCHEMBL20806989 | 0.80 | BCHE (0.44) | IDO1TAAR1 | |
| SCHEMBL14443894 | 0.79 | CYP1A2 (0.49) | MEN1KMT2ALMNAIDO1EPHX1 | |
| SCHEMBL12337765 | 0.78 | IDO1 (0.48) | LMNAIDO1ALDH1A1RAB9ATAAR1 | |
| SCHEMBL9342625 | 0.78 | MEN1 (0.55) | MEN1KMT2ALMNAIDO1EPHX1 | |
| SCHEMBL8007514 | 0.76 | APP (0.44) | IDO1 | |
| SCHEMBL10062558 | 0.76 | CYP1A2 (0.50) | MEN1KMT2ALMNAIDO1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-2102169-B1 | INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-6077866-A | EXHIBIT POWERFUL INSECTICIDAL ACTION, ESPECIALLY AGAINST LEPIDOPTERA, COLEOPTERA AND SOIL INSECTS | NIHON BAYER AGROCHEM K.K. (JP) | 2000-06-20 | — | — | US | disclosed |
| EP-0742202-B1 | Benzophenone hydrazone derivatives as insecticides | BAYER AGROCHEM KK (JP) | 1999-12-01 | — | — | EP | disclosed |
| EP-0742202-A2 | Benzophenone hydrazone derivatives as insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1996-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | MEN1 1522/4885KMT2A 4171/4885LMNA 1618/4885 |
| US-20100197644-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | MEN1 1522/4885KMT2A 4171/4885LMNA 1618/4885 |
| US-20120252770-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | MEN1 1522/4885KMT2A 4171/4885LMNA 1618/4885 |
| US-20110071194-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | MEN1 1522/4885KMT2A 4171/4885LMNA 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.